Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01398839 · ClinicalTrials.gov registry record · Phase 3
Safety Study of the VEGA UV-A System to Treat Ectasia
A Phase 3 study, sponsored by Topcon Medical Systems.
- Terminated
- Registry status
- Phase 3
- Development phase
- 103
- Enrollment target
NCT01398839: Clinical Trial Phase 3 study, sponsored by Topcon Medical Systems.
NCT01398839 is a Phase 3 study that was terminated before completion, run by Topcon Medical Systems. The registered enrollment target is 103 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01398839, a Phase 3 study, was terminated before completion, sponsored by Topcon Medical Systems.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 103 participants
- Enrollment target
Study Summary
The purpose of this research study is to test the safety, tolerability, and effectiveness of corneal collagen cross-linking (CXL) when used to treat ectasia.
Interventions
- DRUG Riboflavin
- DEVICE VEGA UV-A Illumination System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01398839
The ClinicalTrials.gov registry entry for NCT01398839 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Topcon Medical Systems, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Riboflavin is the first listed.
NCT01398839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01398839 about?
NCT01398839 is a clinical study titled "Safety Study of the VEGA UV-A System to Treat Ectasia". The purpose of this research study is to test the safety, tolerability, and effectiveness of corneal collagen cross-linking (CXL) when used to treat ectasia.
What is the current status of trial NCT01398839?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 103 participants. The study started on 2010-12. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01398839?
The interventions under investigation include: Riboflavin (DRUG), VEGA UV-A Illumination System (DEVICE).
Who is sponsoring clinical trial NCT01398839?
This trial is sponsored by Topcon Medical Systems, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.